KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Non-Current Deffered Revenue: 2017-2024

Historic Non-Current Deffered Revenue for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $58.0 million.

  • Moderna's Non-Current Deffered Revenue rose 65.26% to $157.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.0 million, marking a year-over-year increase of 65.26%. This contributed to the annual value of $58.0 million for FY2024, which is 30.12% down from last year.
  • According to the latest figures from FY2024, Moderna's Non-Current Deffered Revenue is $58.0 million, which was down 30.12% from $83.0 million recorded in FY2023.
  • Moderna's 5-year Non-Current Deffered Revenue high stood at $673.0 million for FY2022, and its period low was $58.0 million during FY2024.
  • Its 3-year average for Non-Current Deffered Revenue is $271.3 million, with a median of $83.0 million in 2023.
  • Per our database at Business Quant, Moderna's Non-Current Deffered Revenue soared by 247.46% in 2021 and then crashed by 87.67% in 2023.
  • Moderna's Non-Current Deffered Revenue (Yearly) stood at $177.0 million in 2020, then skyrocketed by 247.46% to $615.0 million in 2021, then rose by 9.43% to $673.0 million in 2022, then slumped by 87.67% to $83.0 million in 2023, then tumbled by 30.12% to $58.0 million in 2024.